Next Article in Journal
Mitigative Effects of PFF-A Isolated from Ecklonia cava on Pigmentation in a Zebrafish Model and Melanogenesis in B16F10 Cells
Next Article in Special Issue
Antifouling Marine Coatings with a Potentially Safer and Sustainable Synthetic Polyphenolic Derivative
Previous Article in Journal
Lipophilic Toxins in Chile: History, Producers and Impacts
Previous Article in Special Issue
Anti-Larval and Anti-Algal Natural Products from Marine Microorganisms as Sources of Anti-Biofilm Agents
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effective Synthesis and Antifouling Activity of Dolastatin 16 Derivatives

1
Division of Environmental Materials Science, Graduate School of Environmental Science, Hokkaido University, Sapporo 060-0810, Japan
2
Sustainable System Research Laboratory, Central Research Institute of Electric Power Industry, Abiko 270-1194, Japan
3
CERES, Inc., Abiko 270-1153, Japan
*
Author to whom correspondence should be addressed.
Mar. Drugs 2022, 20(2), 124; https://doi.org/10.3390/md20020124
Submission received: 29 December 2021 / Revised: 1 February 2022 / Accepted: 1 February 2022 / Published: 4 February 2022
(This article belongs to the Special Issue Marine Natural Products with Antifouling Activity, 2nd Edition)

Abstract

:
Some derivatives of dolastatin 16, a depsipeptide natural product first obtained from the sea hare Dolabella auricularia, were synthesized through second-generation synthesis of two unusual amino acids, dolaphenvaline and dolamethylleuine. The second-generation synthesis enabled derivatizations such as functionalization of the aromatic ring in dolaphenvaline. The derivatives of fragments and whole structures were evaluated for antifouling activity against the cypris larvae of Amphibalanus amphitrite. Small fragments inhibited the settlement of the cypris larvae at potent to moderate concentrations (EC50 = 0.60-4.62 μg/mL), although dolastatin 16 with a substituent on the aromatic ring (24) was much less potent than dolastatin 16.

Graphical Abstract

1. Introduction

Dolastatin 16 (1, Figure 1), a depsipeptide natural product obtained from the sea hare Dolabella auricularia, was first reported by Pettit and co-workers in 1997 [1], and includes two unusual amino acids, dolaphenvaline and dolamethylleuine (Figure 1). Absolute configurations of the two amino acids were determined through X-ray crystallographic analysis in 2011 [2]. Pettit’s group showed strong growth inhibitions of human cancer cell lines such as NCI-H460, KM20L2 and SF-295 with 1 isolated from the natural sample. The same group also synthesized 1, and evaluated the anticancer activities of synthetic 1 to reveal it to be much less potent than the isolated compound [3].
Highly powerful antifouling activity of 1 toward the larval settlement and metamorphosis of the barnacle Amphibalanus amphitrite was shown by Tan and co-workers in 2010 [4]. EC50 (50% effective concentration) and LC50 (50% lethal concentration) values of 1 are 0.003 and 20 μg/mL, respectively, suggesting it to be a promising lead compound for the development of a novel antifouling material. Organotin compounds such as tributyltin (TBT) or triphenyltin (TPT) were employed as antifouling compounds, resulting in serious pollution of the ocean environment [5,6,7,8,9,10,11,12,13,14]. Due to these negative influences, the use of organotin compounds was prohibited by the International Maritime Organization (IMO) in 2008 [15]. Alternative antifouling compounds, sea-nine 211 or copper pyrithione, have also been revealed to exert harmful influence on the ocean environment [16,17]. Thus, green alternative antifouling materials must be found to preserve the ocean environment. Toward this goal, many academic researchers have reported new antifouling compounds derived from natural products [18,19,20,21,22,23,24,25,26,27,28,29,30]. We have also engaged in the study of the antifouling natural products, 10-isocyano-4-cadinene [31,32,33], omaezallene [34,35,36] and dolastatin 16 (1) [37,38].
In 2017, we reported the total synthesis and antifouling activity of 1 and two intermediates, northern carboxylic acid fragment 2 and southern amine fragment 3, to reveal highly potent activity of 1 (EC50 < 0.03 μg/mL) and moderate to low activities of 2 and 3 (EC50 > 10 and 1.17 μg/mL, respectively) [38]. With these results in hand, we envisioned that additional compounds related to 1 would show further potential toward the development of a green antifouling material. For quick access to these compounds, second-generation synthesis of the two unusual amino acids was required because derivatization of the amino acids was difficult with the previous methodology [37]. In this paper, we describe our efforts to synthesize derivatives of dolaphenvaline and dolamethylleuine as well as some derivatives of 1. Evaluations of the antifouling activity toward the cypris larvae of the barnacle A. amphitrite were also conducted.

2. Results and Discussions

For the preparation of dolaphenvaline derivatives, the C-H activation reaction focused on amide 4, which was obtained from l-valine in 3 steps according to known method [39]. The synthetic details to obtain dolaphenvaline derivatives 7 and 8 are shown in Scheme 1. The installment of the aromatic ring on 4 was accomplished in a regio- and diastereoselective manner, confirmed by 1H NMR, in the presence of a palladium catalyst and silver salt without solvent to give amide 5 [39] (see Supplementary Material Figures S1–S14 for NMR spectra). This high diastereoselectivity was rationalized by steric repulsion between the methyl group and the phthaloyl group in the transition state shown in the brackets. Acidic hydrolysis, followed by protection with a Boc group, afforded Boc-dolaphenvaline 7, previously reported by us [37]. First synthesis of 8, having a p-hydroxy group on the benzene ring, was also possible through the same pathway when p-siloxyiodobenzene was employed in the C-H activation step.
Boc-dolamethylleuine 15 was accessed through a [2+2] addition reaction in the presence of organocatalyst 11 as the key step to construct two contiguous asymmetric carbon centers, as shown in Scheme 2 [40]. The reaction between isovaleraldehyde (9) and propionyl chloride (10) at −40 °C provided volatile lactone 12 in a highly stereoselective manner (minor diastereomer could not be observed in crude 1H NMR), which was next converted into carboxylic acid 13 by the treatment with NaN3 and NH4Cl in DMSO. Before the Staudinger reaction, i.e., the conversion of the azide group to an amino group, benzyl ester formation was necessary since the Staudinger reaction of 13 resulted in low yield (<20%). The Staudinger reaction with benzyl ester 14 and subsequent protection with Boc2O proceeded smoothly to give 15 in 59% yield, previously reported by us (specific rotation of the current compound was completely identical with that of the previous one).
With the effective synthetic route to the two unusual amino acids established, we launched the preparation of dolastatin 16 derivatives according to the previous report [38]. Condensation between 8 and proline benzyl ester gave amide 16 in which the hydroxy group was then acetylated under standard conditions (Scheme 3). After hydrogenolysis of peptide 17, coupling of resulting 18 with dolamethylleuine benzyl ester 19 gave peptide 20. In order to proceed with structure-activity relationship studies, 20 was converted into benzyl ether 22 in two steps through methanolysis of the acetate, followed by treatment of the resultant peptide 21 with BnBr, K2CO3 and KI.
Functionalized southern fragment 20 was further coupled with the northern fragment 2 to give peptide 23 for the macrolactonization reaction (Scheme 4). In the previous studies by Pettit and us, Shiina’s conditions by 2-methyl-6-nitrobenzoic anhydride (MNBA) [41,42,43] provided a low yield of 1 (22% by Pettit, 31% by us). In order to improve the reaction yield, extensive optimizations were performed, eventually finding that Mukaiyama’s conditions using 2-chloro-1-methylpyridimium iodide (CMPI) [44] gave the target compound 24 in 64% yield over 2 steps (deprotection of benzyl groups and macrolactonization).
Additional syntheses of northern fragments, benzyl ester 25 and benzyl ether 29, were carried out as shown in Scheme 5. Benzyl ester 25 was prepared by esterification reaction of 2 in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI). For the synthesis of 29, installation of a benzyl group to the prolinol moiety at the stage of 26 was essential because direct etherification into 29 from the corresponding alcohol resulted in a complex mixture. The subsequent condensation reaction between carboxylic acid 28 and the amine obtained by removal of the Boc group of 27 [45] proceeded cleanly to give 29 in good yield.
The antifouling activities of synthetic samples were evaluated as EC50 values against the cypris larvae of A. amphitrite by exposure of each compound for 48 h (Table 1, Figure 2). For comparison, EC50 values for the previous compounds 13 are also shown in the table. Installation of a functional group on the aromatic ring of 1 decreased the antifouling activity to moderate (24, EC50 = 1.74 μg/mL). We next investigated the biological activity of the fragments. All samples showed antifouling profiles with low toxicity against cypris larvae of the barnacle A. amphitrite. Among the fragments examined, compounds Boc-3, 21, and 25 were more active with EC50 values below 1 μg/mL. Protection of the southern fragment with a Boc group improved the EC50 value (Boc-3, EC50 = 0.79 μg/mL). We believe this improvement is due its lower polarity than 3 (EC50 = 1.17 μg/mL) by protection of the amino group. It was revealed that functional groups at the p-position of the aromatic ring affected the antifouling activity of the southern fragment: a hydroxy group (21, EC50 = 0.60 μg/mL) had a slightly decreased EC50 value compared to Boc-3, but a benzyloxy group (22, EC50 = 4.62 μg/mL) dramatically reduced the antifouling activities to 4.62 μg/mL. These results indicate that steric bulkiness at this position affected the activity. A benzyl ester of the northern fragment (25, EC50 = 0.90 μg/mL) showed much higher potency than 2 (EC50 > 10 μg/mL). Again, the less polar fragment was more active than the corresponding more polar one. Interestingly, a benzyl ether (29, EC50 = 3.27 μg/mL) weakened the antifouling activity, suggesting the importance of the lactate moiety or the presence of a carbonyl group for the northern fragment.

3. Materials and Methods

3.1. General Methods

The IR spectra were recorded on a JASCO FTIR-4100 Type A spectrometer (JASCO corporation, Tokyo, Japan) using a NaCl cell. The 1H NMR and 13C NMR spectra were recorded using a JNM-EX 400 (400 MHz and 100 MHz) spectrometer (JEOL Ltd., Tokyo, Japan). Chemical shifts were reported in ppm relative to CHCl3 in CDCl3 for 1H NMR (δ = 7.26) and 13C NMR (δ = 77.0) and CHD2OH in CD3OD for 1H NMR (δ = 3.35) and 13C NMR (δ = 49.3). Splitting patterns for 1H NMR were designated as “s, d, t, q, m, dt, dd, and td”. These symbols indicate “singlet, doublet, triplet, quartet, multiplet, doublettriplet, doubletdoublet, and tripletdoublet”, respectively. All commercially obtained reagents were employed as received. Analytical TLC was carried out using pre-coated silica gel plates (Wako TLC Silicagel 70F254, FUJIFILM Wako Pure Chemical Coporation, Osaka, Japan). Wakogel 60N 63-212 μm was used for column chromatography.

3.2. Pht-Dpv-NH(8-quinoline) 5

Amide 4 (1.00 g, 2.67 mmol), AgOAc (891 mg, 5.36 mmol), Pd(OAc)2 (118 mg, 0.540 mmol) and iodobenzene (0.600 mL, 5.36 mmol) were added to a flask. The mixture was stirred for 6 h at 90 °C under Ar atmosphere. After being cooled to room temperature, the reaction was diluted with AcOEt and then filtered through a pad of celite wash with AcOEt and concentrated in vacuo. The residue was purified by silica gel column chromatography (Hexane:EtOAc = 80:20 then 70:30) to afford 5 (840 mg, 70%) as a white solid: [ α ] D 25 −36.1 (c 0.18, CHCl3); IR (neat) 3650, 2924, 1717, 1530, 1487, 1384, 1327, 1261, 1070, 792, 721 cm–1; 1H NMR (400 MHz, CDCl3) δ 0.87 (3H, d, J = 6.8 Hz), 2.43 (1H, dd, J = 13.4, 10.5 Hz), 3.23 (1H, dd, J = 13.7, 3.4 Hz), 3.36–3.40 (1H, m), 4.88 (1H, d, J = 10.7 Hz), 7.16–7.31 (5H, m), 7.46 (1H, dd, J = 8.3, 4.4 Hz), 7.53 (2H, d, J = 3.4 Hz), 7.74 (2H, dd, J = 5.4, 2.9 Hz), 7.88 (2H, dd, J = 5.4, 2.9 Hz), 8.16 (1H, dd, J = 8.3, 2.0 Hz), 8.77 (1H, t, J = 4.4 Hz), 8.86 (1H, dd, J = 4.4, 2.0 Hz), 10.68 (1H, brs); 13C NMR (CDCl3, 100 MHz) δ 15.9, 34.6, 40.8, 61.7, 117.3, 121.9, 122.3, 124.0, 126.4, 127.5, 128.6, 129.7, 131.8, 134.1, 134.5, 136.5, 139.0, 139.8, 148.8, 166.7, 168.3; HRMS (ESI) m/z:[M + Na]+; Calcd for C28H23N3O3Na 472.1631; Found 472.1632.

3.3. Boc-Dpv-OH 7

Amide 5 (148 mg, 0.330 mmol) was dissolved in 3.0 mL of aqueous HCl (6.0 M) and refluxed for 24 h and then cooled to room temperature. The reaction mixture was concentrated in vacuo. To a solution of compound in THF (3.0 mL), saturated NaHCO3 (3.0 mL) was added Boc2O (151 µL, 0.660 mmol) at 0 °C. The mixture was stirred at room temperature for 24 h. The reaction was diluted with EtOAc, washed with HCl (0.10 M) and brine, dried over Na2SO4. The residue was purified using silica gel column chromatography (Hexane:EtOAc = 50:50) to afford 7 (45.7 mg, 47%) as a colorless oil:

3.4. Pht-Dpv(OTBS)-NH(8-quinoline) 6

Amide 4 (840 mg, 2.24 mmol), AgOAc (750 mg, 4.48 mmol), Pd(OAc)2 (0.100 g, 0.450 mmol), and p-iodophenyl tert-butyldimethylsilyl ether (3.00 g, 8.97 mmol) were added to a flask. The mixture was stirred at 90 °C for 6 h under Ar atmosphere. After being cooled to room temperature, the reaction was diluted with AcOEt and then filtered through a pad of celite wash with AcOEt and concentrated in vacuo. The residue was purified by silica gel column chromatography (Hexane:EtOAc = 90:10 then 80:20) to afford 6 (590 mg, 1.02 mmol, 86%) as a white solid: [ α ] D 25 −56.7 (c 0.45, CHCl3); IR (neat) 2929, 1772, 1718, 1530, 1509, 1382, 1260, 914, 826, 787, 719 cm−1; 1H NMR (400 MHz, CDCl3) δ 0.17 (6H, s), 0.86 (3H, d, J = 7.3 Hz), 0.97 (9H, s), 2.38 (1H, dd, J = 13.7, 10.3 Hz), 3.17 (1H, dd, J = 13.7, 3.4 Hz), 3.33–3.35 (1H, m), 4.88 (1H, d, J = 10.7 Hz), 6.74 (2H, d, J = 7.6 Hz), 7.16 (2H, d, J = 7.6 Hz), 7.43 (1H, dd, J = 8.3, 4.4 Hz), 7.51 (2H, d, J = 3.4 Hz), 7.71 (2H, dd, J = 5.4, 2.9 Hz), 7.87 (2H, dd, J = 5.4, 2.9 Hz), 8.13 (1H, dd, J = 8.3, 1.5 Hz), 8.78 (1H, dd, J = 5.4, 3.4 Hz), 8.84 (1H, dd, J = 4.4, 1.5 Hz), 10.68 (1H, brs); 13C NMR (100 MHz, CDCl3) δ 4.5, 15.6, 18.1, 25.6, 34.4, 61.4, 117.0, 119.7, 121.6, 122.0, 123.4, 127.2, 127.8, 130.2, 131.5, 132.1, 134.1, 136.1, 138.7, 148.5, 153.9, 166.5, 168.0; HRMS (ESI) m/z: [M + Na]+; Calcd for C34H37N3O4SiNa 602.2447; Found 602.2446.

3.5. Boc-Dpv(OH)-OH 8

Amide 6 (290 mg, 0.500 mmol) was dissolved in 14 mL of aqueous HCl (6.0 M) was heated at 130 °C in a sealed tube for 24 h and then cooled to room temperature. The reaction mixture was concentrated in vacuo. To a solution of compound in THF (2.5 mL), saturated NaHCO3 (2.5 mL) was added Boc2O (0.200 mL, 1.00 mmol) at 0 °C. The mixture was stirred at room temperature for 24 h. The solution was diluted with EtOAc, washed with HCl (0.1 M) and brine, dried over Na2SO4. The residue was purified using silica gel column chromatography (Hexane:EtOAc = 50:50) to afford 8 (120 mg, 0.387 mmol, 77%) as a colorless oil: [ α ] D 25 +3.5 (c 0.49, CH3OH); IR (neat) 3748, 2976, 1702, 1514, 1398, 1244, 1160, 1073, 774, 641 cm−1; 1H NMR (400 MHz, CDCl3) δ 0.86 (3H, brs), 1.47 (9H, s), 2.33–2.43 (1H, m), 2.62–2.66 (1H, m), 4.34 (1H, brs), 5.10 (1H, d, J = 9.3 Hz), 6.73 (2H, d, J = 7.8 Hz), 6.98 (2H, d, J = 7.8 Hz); 13C NMR (100 MHz, CD3OD) δ 4.7, 28.4, 38.6, 39.8, 57.7, 80.3, 115.9, 129.6, 130.8, 131.8, 156.5, 171.0; HRMS (ESI) m/z: [M + Na]+; Calcd for C16H23NO5Na 332.1471; Found 332.1468.

3.6. N2-Dml-OH 13

Lithium perchlorate (2.12 g, 20.0 mmol), was dissolved in 10 mL anhydrous Et2O. TMS-quinine 11 (400 mg, 1.00 mmol) and CH2Cl2 (20 mL) were added to this solution which was then cooled to −40 °C. DIEA (4.36 mL, 25.0 mmol) and isobutyraldehyde (0.920 mL, 10.0 mmol) were then added to the solution. Propionyl chloride (1.74 mL, 20.0 mmol) was dissolved in CH2Cl2 (5.0 mL). The solution of propionyl chloride was then added dropwise to the reaction over the course of 3 h. Upon completion of the addition, the reaction was allowed to stir at −40 °C for 16 h. After this time, Et2O was added to the solution. The resulting mixture was filtered through a pad of celite and washed with Et2O. The solution was concentrated at a light vacuum and diluted with CH2Cl2. The solution was washed with sat. NH4Cl and brine, dried over Na2SO4 and concentrated at a light vacuum to give crude lactone, which was used in the next step without further purification.
To a solution of the crude lactone in DMSO (30 mL) were added NaN3 (1.30 g, 20.0 mmol) and NH4Cl (535 mg, 10.0 mmol) at room temperature. The mixture was heated at 50 °C, diluted with aqueous HCl, extracted with EtOAc, washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (Hexane:EtOAc = 20:80) to afford 14 (718 mg, 4.20 mmol, 42%) as a colorless oil: [ α ] D 20 +8.1 (c 0.92, CHCl3); IR (neat) 2967, 2878, 2157, 2106, 1713, 1419, 893, 852, 663 cm−1; 1H NMR (400 MHz, CDCl3) δ 0.89 (3H, d, J = 6.8 Hz), 1.08 (3H, d, J = 6.8 Hz), 1.23 (3H, d, J = 7.3 Hz), 1.95–2.05 (1H, m), 2.61–2.68 (1H, m), 3.42 (1H, dd, J = 8.8, 4.4 Hz); 13C NMR (100 MHz, CDCl3) δ 14.5, 15.7, 20.5, 29.5, 42.4, 70.6, 180.4; HRMS (ESI) m/z: [M + Na]+; Calcd for C7H13N3O2Na 194.0906; Found 194.0910.

3.7. N2-Dml-OBn 14

To a solution of 13 (20.0 mg, 0.120 mmol) in DMF (0.60 mL) were added BnBr (0.0200 mL, 0.180 mmol), NaH (4.00 mg, 0.160 mmol) at 0 °C under Atmosphere. The mixture was stirred at room temperature for overnight, quenched with saturated NaHCO3, extracted with EtOAc, washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (Hexane:EtOAc = 20:80) to afford 14 (20.0 mg, 0.0800 mmol, 64%) as a colorless oil: [ α ] D 18 +19.8 (c 0.68, CHCl3); IR (neat) 2966, 2103, 1734, 1456, 1366, 1341, 1261, 1171, 1147, 1027, 978, 907, 751, 697 cm−1; 1H NMR (400 MHz, CDCl3) δ 0.86 (3H, d, J = 6.8 Hz), 1.05 (3H, d, J = 6.8 Hz), 1.17 (3H, d, J = 7.3 Hz), 1.93–1.99 (1H, m), 2.62–2.69 (1H, m), 3.45 (1H, dd, J = 9.3, 3.9 Hz), 5.17 (1H, s), 7.25–7.37 (5H, m); 13C NMR (100 MHz, CDCl3) δ14.5, 15.5, 20.6, 29.3, 42.7, 66.6, 70.8, 128.27, 128.28, 128.5, 135.7, 174.4; HRMS (ESI) m/z: [M + Na]+; Calcd for C14H19N3O2Na 284.1375; Found 284.1377.

3.8. Boc-Dml-OBn 15

To a solution of 14 (1.52 g, 5.82 mmol) in THF/water (10:1 v/v, 29 mL) were added Ph3P (4.60 g, 17.4 mmol) at 60 °C for 2 h. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue obtained was dissolved in THF/NaHCO3 (1:1 v/v, 17 mL). Cool the solution to 0 °C, add Boc2O (1.60 mL, 6.80 mmol), return to ambient temperature and stir overnight. Extracted with EtOAc, washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (Hexane:EtOAc = 20:80) to afford 15 (1.09 g, 3.40 mmol, 59%) as a colorless oil: [ α ] D 25 +18.1 (c 0.23, CHCl3); IR (neat) 3750, 2974, 2876, 1716, 1507, 1166, 772, 669 cm−1; 1H NMR (400 MHz, CDCl3) δ 0.89 (3H, d, J = 6.8 Hz), 0.91 (3H, d, J = 6.8 Hz), 1.22 (3H, d, J = 6.8 Hz), 1.43 (9H, s), 1.61 (1H, sep, J = 6.8 Hz), 2.80-2.87 (1H, m), 3.38 (1H, ddd, J = 10.1, 7.3, 4.4 Hz), 5.10 (1H, d, J = 15.6 Hz), 5.11 (1H, d, J = 15.6 Hz), 5.24 (1H, d, J = 10.2 Hz), 7.32 -7.39 (5H, m); 13C NMR (100 MHz, CDCl3) δ 15.7, 19.2, 19.9, 28.4, 31.8, 40.5, 58.6, 66.3, 78.8, 128.1, 128.3, 128.6, 135.7, 156.4, 175.6; HRMS (ESI) m/z: [M + Na]+ Calcd for C19H29NO4Na 358.1989; Found 358.1992.

3.9. Boc-Dpv(OH)-Pro-OBn 16

To a solution of 8 (850 mg, 2.70 mmol) and L-proline benzylester (670 mg, 3.24 mmol) in CH3CN (13.5 mL) was added EDCI (620 mg, 3.24 mmol), HOAt (440 mg, 3.24 mmol) and NaHCO3 (230 mg, 2.70 mmol) under Ar atmosphere. After 24 h of stirring at room temperature, the mixture was concentrated in vacuo. The residue was purified using silica gel column chromatography (Hexane:EtOAc = 50:50) to afford the dipeptide 16 (1.02 g, 2.05 mmol, 76%) as colorless oil: [ α ] D 25 −35.4 (c 1.20, CHCl3); IR (neat) 3326, 2927, 2931, 1744, 1715, 1637, 1514, 1260, 1168, 1016, 753 cm−1; 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 0.85 (3H, d, J = 6.8 Hz), 1.45 (9H, s), 1.82–1.89 (2H, m), 2.01–2.02 (1H, m), 2.13–2.17 (1H, m), 2.35 (1H, dd, J = 13.7, 7.3 Hz), 2.67 (1H, dd, J = 13.7, 6.8 Hz), 3.18–3.24 (1H, m), 3.30–3.32 (1H, m), 4.41 (1H, d, J = 6.3 Hz), 4.55 (1H, dd, J = 8.3, 4.4 Hz), 5.13 (2H, s), 5.30 (1H, d, J = 9.8 Hz), 5.91 (1H, brs), 6.74 (2H, d, J = 8.3 Hz), 7.05 (2H, d, J = 8.3 Hz), 7.28–7.33 (5H, m); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 14.2, 15.3, 24.9, 28.4, 28.9, 36.3, 38.4, 39.1, 46.5, 58.8, 65.9, 66.9, 115.1, 128.1, 128.3, 128.5, 130.5, 132.2, 135.6, 154.2, 171.9; HRMS (ESI) m/z: [M + Na]+; Calcd for C28H36N2O6Na 519.2465; Found 519.2466.

3.10. Boc-Dpv(OAc)-Pro-OBn 17

To a solution of 16 (520 mg, 1.05 mmol) in CH2Cl2 (5.25 mL) was added Ac2O (120 μL, 1.26 mmol) and DMAP (50.0 mg, 0.42 mmol) under Ar atmosphere. After 2 h of stirring at room temperature, the mixture was concentrated in vacuo. The residue was purified using silica gel column chromatography (Hexane:EtOAc = 50:50) to afford the dipeptide 17 (510 mg, 0.97 mmol, 92%) as colorless oil: [ α ] D 25 −38.7 (c 1.20, CHCl3); IR (neat) 3735, 3308, 2970, 2963, 2931, 1744, 1715, 1651, 1510, 1433, 1168, 753, 711 cm−1; 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 0.84 (3H, d, J = 6.8 Hz), 1.34 (9H, s), 1.72–1.89 (3H, m), 1.97–2.07 (1H, m), 2.13–2.17 (1H, m), 2.25 (3H, s), 2.35 (1H, dd, J = 13.7, 7.3 Hz), 2.67 (1H, dd, J = 13.7, 6.8 Hz), 3.17–3.24 (1H, m), 3.29–3.32 (1H, m), 4.41 (1H, d, J = 6.3 Hz), 4.55 (1H, dd, J = 8.3, 4.4 Hz), 5.13 (2H, s), 5.30 (1H, d, J = 9.8 Hz), 5.91 (1H, brs), 6.74 (2H, d, J = 8.3 Hz), 7.05 (2H, d, J = 8.3 Hz), 7.28–7.33 (5H, m); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 14.3, 15.3, 24.0, 28.2, 28.9, 36.3, 37.8, 39.1, 46.5, 58.8, 65.9, 67.0, 115.1, 128.1, 128.2, 128.5, 130.5, 132.2, 135.6, 154.2, 172.3; HRMS (ESI) m/z: [M + Na]+; Calcd for C30H39N2O7Na 562.2463; Found 562.2467.

3.11. Boc-Dpv(OAc)-Pro-Dml-OBn 20

To 15 (1.09 g, 3.40 mmol) was added TFA/CH2Cl2 (1:4 v/v, 25 mL). After 1 h of stirring at room temperature, the solution was concentrated in vacuo to afford crude 19, which was used in the next step without further purification.
To a solution of 17 (550 mg, 1.05 mmol) in CH3OH (5.25 mL) was carefully added Pd(OH)2/C (110 mg, 20 wt%) under Ar atmosphere. The solution was purged with H2 gas and stirring was continued under H2 atmosphere at room temperature for 16 h. The solution was filtered through celite and concentrated in vacuo to afford crude 18, which was used in the next step without further purification.
To a solution of the crude 19 (610 mg, 2.60 mmol) and crude 18 (1.25 g, 2.60 mmol) in CH3CN (26 mL) were added DMTMM (740 mg, 2.60 mmol) and Et3N (2.17 mL, 15.6 mmol) under Ar atmosphere. After 24 h of stirring at room temperature, the mixture was concentrated in vacuo. The residue was purified using silica gel column chromatography (Hexane:EtOAc = 20:80) to afford 20 (1.01 g, 1.51 mmol, 58%) as a colorless oil: [ α ] D 25 +8.8 (c 2.40, CHCl3); IR (neat) 3734, 3413, 3309, 2973, 2877, 1715, 1507, 1366, 1168, 754 cm−1; 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 0.85 (3H, d, J = 6.8 Hz), 0.86 (3H, d, J = 6.8 Hz), 0.88 (3H, d, J = 6.8 Hz), 1.17 (3H, d, J = 7.3 Hz), 1.46 (9H, s), 1.89 (2H, t, J = 5.4 Hz), 1.98–2.09 (2H, m), 2.17–2.23 (1H, m), 2.26 (3H, s), 2.48 (1H, dd, J = 13.7, 6.8 Hz), 2.74 (1H, dd, J = 13.2, 7.8 Hz), 2.86 (1H, dd, J = 6.8, 3.4 Hz), 3.15–3.18 (1H, m), 3.23–3.28 (1H, m), 3.68 (1H, td, J = 9.8, 3.4 Hz), 4.47–4.52 (2H, m), 5.01 (1H, d, J = 12.2 Hz), 5.06 (2H, d, J = 12.2 Hz), 5.37 (1H, d, J = 9.8 Hz), 6.80 (1H, d, J = 10.7 Hz), 6.98 (2H, d, J = 8.8 Hz), 7.29–7.37 (7H, m); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 0.3, 14.5, 16.2, 19.8, 20.1, 21.4, 25.2, 28.6, 28.7, 29.4, 32.2, 38.9, 40.0, 47.0, 53.8, 57.3, 61.0, 66.6, 79.8, 121.7, 128.3, 128.6, 128.9, 130.8, 135.9, 138.4, 149.3, 169.7, 171.8, 172.1, 176.3; HRMS (ESI) m/z: [M + Na]+; Calcd for C37H51N3O8Na 688.3566; Found 688.3568.

3.12. Boc-Dpv(OH)-Pro-Dml-OBn 21

To a solution of 20 (184 mg, 0.276 mmol) in CH3OH (0.14 mL) were added TEA (7.00 µL, 0.502 µmol) under Ar atmosphere. After 24 h of stirring at room temperature, the mixture was concentrated in vacuo. The crude product was purified using silica gel column chromatography (Hexane:Acetone = 75:25) to afford 21 (155 mg, 0.0205 mmol, 90%) as a colorless foam: [ α ] D 23 +6.3 (c 1.18, CHCl3); IR (neat) 3403, 3311, 3009, 2975, 2935, 2878, 1715, 1652, 1615, 1594, 1516, 1455, 1391, 1367, 1235, 1172, 1101, 1057, 1003, 877, 826, 755, 698, 666 cm−1; 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 0.72–0.94 (9H, m), 1.20 (3H, d, J = 7.3 Hz), 1.35–1.58 (10H, m), 1.70–1.92 (2H, m), 1.96–2.10 (4H, m), 2.15–2.25 (1H, m), 2.40 (1H, dd, J = 13.7, 6.8 Hz), 2.59–2.69 (1H, m), 2.81–2.92 (1H, m), 3.21–3.35 (2H, m), 3.69 (1H, td, J = 9.76, 3.4 Hz), 4.45–4.55 (2H, m), 5.06 (2H, s), 5.38 (1H, d, J = 9.8 Hz), 6.74 (2H, d, J = 8.3 Hz), 6.90 (1H, d, J = 10.2 Hz), 7.06 (2H, d, J = 7.8 Hz), 7.18–7.41 (5H, m); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 13.9, 15.8, 19.6, 19.8, 24.9, 28.3, 29.1, 31.8, 38.0, 39.5, 39.7, 46.7, 53.7, 57.2, 60.6, 66.3, 79.8, 115.1, 128.0, 128.1, 128.3, 128.5, 128.6, 130.1, 130.3, 131.1, 135.5, 155.0, 156.2, 171.9, 172.1, 175.9; HRMS (ESI) m/z: [M + Na]+ Calcd for C35H49N3O7Na 646.3478; Found 646.3463

3.13. Boc-Dpv(OBn)-Pro-Dml-OBn 22

To a solution of 21 (12.1 mg, 0.0194 mmol) in CH3CN (0.16 mL) were added K2CO3 (8.90 mg, mmol), BnBr (8.00 µL, 0.0669 mmol) and KI (1.10 mg, 6.63 µmol) under Ar atmosphere at room temperature. The mixture was stirred for 24 h, quenched with sat. NaHCO3, extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (Hexane:Acetone = 80:20) to afford 22 (14.6 mg, 0.0205 mmol, 95%) as a colorless oil: [ α ] D 29 +13.1 (c 1.22, CHCl3); IR (neat) 3416, 3315, 2972, 2932, 2876, 1714, 1652, 1507, 1456, 1417, 1392, 1367, 1241, 1172, 1099, 1026, 907, 808, 751, 697, 666 cm−1; 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 0.72–0.95 (9H, m), 1.17 (3H, d, J = 7.3 Hz), 1.35–1.52 (10H, m), 1.79–2.23 (5H, m), 2.44 (1H, dd, J = 13.7, 6.8 Hz), 2.61–2.75 (1H, m), 2.80–2.92 (1H, m), 3.20–3.39 (2H, m), 3.69 (1H, td, J = 10.1, 3.4 Hz), 4.41–4.59 (2H, m), 4.92–5.08 (4H, m), 5.35 (1H, d, J = 8.8 Hz), 6.72–6.95 (3H, m), 7.15–7.50 (12H, m); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 14.0, 15.9, 19.5, 19.8, 24.9, 29.2, 29.6, 31.7, 31.8, 38.4, 39.6, 39.7, 46.7, 53.4, 53.8, 53.8, 57.0, 60.6, 66.3, 69.9, 79.5, 114.6, 127.3, 127.8, 128.0, 128.3, 128.5, 128.6, 130.4, 132.7, 135.6, 137.1, 155.9, 157.1, 171.5, 172.0, 175.9; HRMS (ESI) m/z: [M + Na]+ Calcd for C42H55N3O7Na 736.3932; Found 736.3931.

3.14. BnO-Lac-Pro-O-Hiv-D-MeVal-Pro-Dpv(OAc)-Pro-Dml-OBn 23

To 20 (380 mg, 0.570 mmol) was added TFA/CH2Cl2 (1:4 v/v, 19 mL). After 1 h of stirring at room temperature, the solution was concentrated in vacuo to afford crude amine, which was used in the next step without further purification.
To a solution of the crude amine and 2 (340 mg, 0.570 mmol) in CH3CN (5.70 mL) were added Et3N (0.480 mL, 3.42 mmol) and DMTMM (160 mg, 0.570 mmol) under Ar atmosphere. After 24 h of stirring at room temperature, the solution was concentrated in vacuo. The residue was purified using silica gel column chromatography to afford 23 (368 mg, 0.325 mmol, 57% over 2 steps) as a colorless foam: [ α ] D 25 −12.7 (c 1.20, CHCl3); IR (neat) 3733, 3410, 3309, 2973, 2965, 2876, 1730, 1663, 1510, 1430, 1183, 1100, 753 cm−1; 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 0.69–1.17 (20H, m), 1.24–1.27 (4H, m), 1.38–1.59 (4H, m), 1.70–2.16 (9H, m), 2.28 (3H, s), 2.23–2.94 (11H, m), 3.08 (3H, s), 3.10–3.77 (5H, m), 4.05–4.93 (11H, m), 6.78 (0.5H, d, J = 10.3 Hz), 6.95 (1.5H, d, J = 8.3 Hz), 7.23–7.35 (14H, m); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ13.8, 14.2, 15.83, 15.85, 16.0, 16.6, 17.0, 17.2, 17.8, 18.0, 19.2, 19.4, 19.60, 19.67, 19.7, 20.0, 20.9, 21.0, 24.6, 24.9, 25.5, 26.3, 29.0, 29.8, 30.0, 31.7, 31.8, 38.6, 39.5, 46.6, 46.7, 56.8, 58.6, 59.1, 59.9, 60.5, 60.6, 66.15, 66.19, 70.8, 71.0, 74.8, 75.6, 121.1, 121.2, 127.56, 127.59, 127.77, 127.82, 127.84, 128.23, 128.25, 128.27, 128.4, 128.5, 130.3, 130.4, 135.4, 137.6, 137.9, 148.8, 167.5, 169.2, 169.7, 170.9, 171.0, 171.2, 171.3, 171.5, 171.6, 175.86, 175.88; HRMS (ESI) m/z: [M + Na]+; Calcd for C63H86N13O6Na 1157.3893; Found 1157.6145.

3.15. Dolastatin 16 Acetate 24

To a solution of 23 (110 mg, 0.100 mmol) in CH3OH (1.00 mL) was carefully added Pd(OH)2/C (22.0 mg, 20 wt%) under Ar atmosphere. The solution was purged with H2 gas and stirring was continued under H2 atmosphere at room temperature for 16 h. The solution was filtered through celite and concentrated in vacuo to afford crude carboxylic acid, which was used in the next step without further purification.
A solution of the crude carboxylic acid 10a (9.50 mg, 0.0100 mmol) in CH3CN (6.3 mL) was dropwised to a refluxing solution of 2-chloro-1-methylpyridinium iodide (13.0 mg, 0.0130 mmol) and Et3N (0.0150 mL, 0.110 mmol) in CH3CN (3.1 mL) over a 3 h period via addition funnel. The addition funnel was rinsed with a total of 0.6 mL of CH3CN. The mixture was refluxed for overnight. After being cooled to ambient temperature, the mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography on silica gel (Hexane:EtOAc = 20:80) to afford 24 as a colorless oil (4.90 mg, 0.005 mmol, 64% over 2 steps): [ α ] D 25 +29.4 (c 0.38, CHCl3); IR (neat) 3394, 3324, 2965, 2876, 1750, 1732, 1650, 1507, 1458, 1426, 1386, 1298, 1194, 1090, 1019, 753, 666 cm−1; 1H NMR (400 MHz, CDCl3) δ 0.82–0.93 (14H, m), 1.01–1.09 (9H, m), 1.43 (3H, d, J = 6.8 Hz), 1.45–1.60 (2H, m), 1.65–2.26 (9H, m), 2.28 (3H, s), 2.30–2.44 (6H, m), 2.45–2.55 (2H, m), 2.78–2.90 (2H, m), 3.08 (3H, s), 3.35–3.50 (2H, m), 3.60–3.70 (2H, m), 3.85–3.92 (1H, m), 4.44 (1H, d, J = 6.8 Hz), 4.54 (1H, d, J = 7.8 Hz), 4.60–4.64 (1H, m), 4.94 (1H, d, J = 8.8 Hz), 5.12–5.20 (2H, m), 5.41 (1H,d, J = 2.9 Hz), 6.72 (1H, d, J = 8.8 Hz), 6.74 (1H, d, J = 8.7 Hz), 7.00 (2H, d, J = 8.3 Hz), 7.41 (2H, d, J = 8.8 Hz), 7.68 (1H, d, J = 10.2 Hz); 13C NMR (100 MHz, CDCl3) δ 14.8, 15.2, 16.0, 17.1, 17.7, 19.6, 19.7, 20.3, 21.1, 21.7, 24.7, 24.8, 24.9, 25.4, 25.5, 28.2, 29.5, 30.6, 30.7, 32.2, 38.6, 41.0, 45.9, 46.4, 47.5, 50.2, 56.2, 57.8, 58.8, 59.4, 59.5, 61.2, 66.6, 120.1, 121.4, 130.6, 138.2, 149.0, 161.8, 169.0, 169.50, 169.54, 170.95, 170.99, 171.1, 172.3, 174.6; HRMS (ESI) m/z: [M + Na]+; Calcd for C49H72N6O12Na 959.5108; Found 959.5100.

3.16. BnO-Lac-Pro-O-Hiv-D-MeVal-Pro-OBn 25

To a solution of 2 (6.3 mg, 0.0107 mmol) in CH2Cl2 (0.30 mL) were added BnOH (1.30 μL, 0.0126 mmol), DMAP (catalytic) and EDCI (3.00 mg, 0.0156 mmol) under Ar atmosphere. The mixture was stirred for 27 h at room temperature and concentrated in vacuo. The crude product was purified using column chromatography (5% EtOAc in hexane) to afford 25 (4.70 mg, 0.00694 mmol, 64%) as a colorless oil:
[ α ] D 21 +35.1 (c 0.47, CHCl3); IR (neat) 2963, 2927, 2874, 1742, 1646, 1454, 1426, 1370, 1295, 1255, 1186, 1092, 1014, 738, 699 cm−1; 1H NMR (CDCl3, 400 MHz, mixture of rotamers) δ 0.68–1.01 (12H, m), 1.33–1.42 (3H, m), 1.70–2.32 (10H, m), 2.82 (2H, s), 2.95 (1H, s), 3.30–3.72 (4H, m), 4.10–4.35 (2H, m), 4.40–4.75 (3H, m), 4.90–5.10 (4H, m), 7.19–7.31 (10H, m); 13C NMR (CDCl3, 100 MHz, mixture of rotamers) δ 14.1, 15.9, 16.1, 17.1, 17.2, 17.8, 19.7, 19.8, 20.1, 24.9, 25.1, 26.2, 26.3, 28.0, 28.8, 28.90, 28.99, 29.6, 29.81, 29.85, 46.52, 46.56, 58.5, 58.8, 59.1, 60.1, 66.7, 67.1, 70.9, 72.6, 75.2, 75.4, 77.2, 127.6, 127.72, 127.75, 128.1, 128.2, 128.31, 128.38, 128.52, 128.58, 135.5, 137.7, 167.8, 168.1, 169.1, 169.6, 171.3, 171.71, 171.78, 172.0, 172.3; HRMS (ESI) m/z: [M + Na]+ Calcd for C38H51N3O8Na 700.3574; Found 700.3578.

3.17. Boc-Pro-O-Hiv-D-MeVal-Pro-CH2OBn 29

To peptide 2745 (51.4 mg, 0.127 mmol) was added TFA/DCM (1:4 v/v, 2.2 mL). After 1 h of stirring at room temperature, the mixture was concentrated in vacuo. The residue TFA salt was added 0.5 M NaOH aq, extracted with DCM, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to afford crude amine, which was used in the next step without further purification.
To a solution of the crude amine in MeCN (0.65 mL) was added 4 N HCl in dioxane (31.0 µL, 0.127 mmol) under Ar atmosphere. After 30 min of stirring at room temperature, to the mixture were added 28 (51.5 mg, 0.127 mmol), PyBroP (71.1 mg, 0.152 mmol) and iPr2NEt (66.0 µL, 0.381 mmol) The mixture was stirred for 24 h, quenched with sat. NH4Cl, extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (Hexane:Acetone = 80:20) to afford 29 (56.1 mg, 0.0932 mmol, 73%) as a colorless oil: [ α ] D 21 +18.0 (c 1.03, CHCl3); IR (neat), 2970, 2933, 2875, 1747, 1701, 1643, 1454, 1397, 1365, 1297, 1254, 1188, 1168, 1119, 1088, 1029, 1011, 917, 890, 772, 740, 699 cm−1; 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 0.80 (3H, t, J = 7.3 Hz), 0.85–1.13 (9H, m), 1.32–1.52 (9H, m), 1.69–2.41 (10H, m), 2.89 (1.9H, s), 2.97 (0.5H, s), 2.99 (0.6H, s), 3.25–3.59 (5.5H, m), 3.60–3.70 (0.5H, m), 4.23–4.38 (1.5H, m), 4.40–4.60 (2.5H, m), 4.94 (0.6H, d, J = 10.7 Hz), 4.95–5.05 (1H, m), 5.20 (0.4H, dd, J = 10.7, 8.3), 7.22–7.40 (5H, m); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 16.3, 16.3, 16.4, 18.1, 18.2, 19.5, 19.6, 19.6, 19.7, 19.8, 20.0, 20.0, 21.7, 23.2, 24.0, 24.0, 26.5, 26.5, 27.4, 28.1, 28.3, 28.5, 28.5, 28.8, 29.0, 29.1, 29.6, 29.9, 29.9, 29.9, 30.4, 30.5, 45.7, 46.3, 46.3, 46.9, 55.5, 56.6, 56.6, 58.2, 58.5, 58.5, 59.5, 60.3, 60.3, 69.6, 71.3, 72.8, 73.0, 75.1, 75.2, 75.5, 79.6, 79.6, 79.7, 127.4, 127.4, 127.5, 127.6, 128.3, 128.4, 138.6, 153.9, 167.8, 168.0, 169.2, 127.8; HRMS (ESI) m/z: [M + Na]+ Calcd for C33H51O7N3Na 524.3614; Found 524.3619.

3.18. Antifouling Assay

Antifouling assay against larvae of the barnacle Amphibalanus amphitrite was conducted according to the previous literature [18,19,38]. The adult barnacles, A. amphitrite, obtained from oyster farms in Lake Hamana and a pier of Shimizu bay, Shizuoka, were kept in an aquarium at 20 °C and were fed on Artemia salina nauplii. Broods were released as I–II stage nauplii upon immersion in seawater after drying overnight. The nauplii (1.0~3.0 indiv./mL) thus obtained were cultured in 2.0 L filtered (0.2 μm) natural seawater (diluted by DW: salinity 28) containing penicillin G (20 μg/mL) and streptomycin sulfate (30 μg/mL) at 25 °C and were fed on the diatom Chaetoceros gracillis at concentrations of 40 × 104 cells/mL. Larvae reached the cyprid stage in 5 days. The cyprids were collected, then stored at 4 °C until use (0-day-old).
The test compounds were dissolved in ethanol and aliquots of the solution (20 μL) were transferred to wells of a 24-well polystyrene culture plates and then air-dried for 3 h at room temperature and CuSO4 was used as positive compound. Four wells were used for each concentration (0.03, 0.1, 0.3, 1.0, 3.0, 10.0 μg/mL). To each well were added filtered (0.2 mm) natural seawater (2.0 mL, salinity 28) and six 2-day-old cyprids. The plates were kept in the dark at 25 °C for 48 h. The numbers of cyprids that attached, metamorphosed, died, or did not settle were counted under a microscope. Three or four trials were carried out for each concentration. Antifouling activity (EC50) indicates the concentration reducing the larval settlement to 50% of the control (non-treatment) by Probit analysis. Toxicity of compounds were expressed as LC50 value, which indicates the concentration showing 50% mortality estimated by Probit analysis. If mortality rate did not show over 50% at most hagh concentration (10.0 μg/mL), then LC50 value was indicated as over 10.0 μg/mL.

4. Conclusions

In summary, we have developed new methodologies for the derivatives of the two unusual amino acids found in dolastatin 16 through a C-H activation reaction for dolaphenvaline and an enantio- and diastereoselective [2+2] addition reaction for dolamethylleuine. These synthetic routes enabled effective access to especially the southern fragment of dolastatin 16. Many trends of the derivatives towards antifouling activity were exhibited. Specifically, less polar small fragments showed strong antifouling activity against the cypris larvae of A. amphitrite without detectable toxicity, although the whole structure was required for extremely potent activity. These results will be useful toward the development of green antifouling materials, and further studies are in progress in our laboratory.

Supplementary Materials

The following are available online at www.mdpi.com/article/10.3390/md20020124/s1, NMR spectra of synthetic samples. Figure S1: 1H and 13C NMR spectra of compound 5. Figure S2: 1H and 13C NMR spectra of compound 6. Figure S3: 1H and 13C NMR spectra of compound 8. Figure S4: 1H and 13C NMR spectra of compound 13. Figure S5: 1H and 13C NMR spectra of compound 14. Figure S6: 1H and 13C NMR spectra of compound 16. Figure S7: 1H and 13C NMR spectra of compound 17. Figure S8: 1H and 13C NMR spectra of compound 20. Figure S9: 1H and 13C NMR spectra of compound 21. Figure S10: 1H and 13C NMR spectra of compound 22. Figure S11: 1H and 13C NMR spectra of compound 23. Figure S12: 1H and 13C NMR spectra of compound 24. Figure S13: 1H and 13C NMR spectra of compound 25. Figure S14: 1H and 13C NMR spectra of compound 29.

Author Contributions

T.U. and F.M. designed the study; L.O.C., K.K., Y.H., K.N. and A.Y. synthesized the compounds; Y.N. and E.Y. performed the evaluations of the synthetic samples; T.U. acquired the funds; T.U., Y.N., and F.M. analyzed the data and wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by JSPS Kakenhi (Grant Nos. 15K16551 and 18H02271).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Data are contained within the article or Supplementary Materials.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

EDCI1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride,
HOAt1-hydroxy-7-azabenzotriazole,
DMTMM4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate,
PyBropbromotripyrrolidinophosphonium hexafluorophosphate.

References

  1. Pettit, G.R.; Xu, J.-P.; Hogan, F.; Williams, M.D.; Doubek, D.L.; Schmidt, J.M.; Cerny, R.L.; Boyd, M.R. Isolation and Structure of the Human Cancer Cell Growth Inhibitory Cyclodepsipeptide Dolastatin 16. J. Nat. Prod. 1997, 60, 752–754. [Google Scholar] [CrossRef]
  2. Pettit, G.R.; Smith, T.H.; Xu, J.-P.; Herald, D.L.; Flahive, E.J.; Anderson, C.R.; Belcher, P.E.; Knight, J.C. Antineoplastic Agents. 590. X-ray Crystal Structure of Dolastatin 16 and Syntheses of the Dolamethylleuine and Dolaphenvaline Units. J. Nat. Prod. 2011, 74, 1003–1008. [Google Scholar] [CrossRef] [Green Version]
  3. Pettit, G.R.; Smith, T.H.; Arce, P.M.; Flahive, E.J.; Anderson, C.R.; Chapuis, J.-C.; Xu, J.-P.; Groy, T.L.; Belcher, P.E.; Macdonald, C.B. Antineoplastic Agents. 599. Total Synthesis of Dolastatin 16. J. Nat. Prod. 2015, 78, 476–485. [Google Scholar] [CrossRef]
  4. Tan, L.K.; Goh, B.P.L.; Tripathi, A.; Lim, M.G.; Dickinson, G.H.; Lee, S.S.C.; Teo, S.L.M. Natural antifoulants from the marine cyanobacterium Lyngbya majuscule. Biofouling 2010, 26, 685–695. [Google Scholar] [CrossRef]
  5. Brooks, S.J.; Waldock, M. Copper Biocides in the Marine Environment. In Ecotoxicology of Antifouling Biocides; Arai, T., Harino, H., Ohji, M., Langston, W.J., Eds.; Springer: Tokyo, Japan, 2009; p. 414. [Google Scholar]
  6. Shimasaki, Y.; Kitano, T.; Oshima, Y.; Inoue, S.; Imada, N.; Honjo, T. Tributyltin causes masculinization in fish. Environ. Toxicol. Chem. 2003, 22, 141–144. [Google Scholar] [CrossRef]
  7. McAllister, B.G.; Kime, D.E. Early life exposure to environmental levels of the aromatase inhibitor tributyltin causes masculinisation and irreversible sperm damage in zebrafish (Danio rerio). Aquat. Toxicol. 2003, 65, 309–316. [Google Scholar] [CrossRef]
  8. Weis, J.S.; Perlmutter, J. Effects of Tributyltin on Activity and Burrowing Behavior of the Fiddler Crab, Uca pugilator. Estuaries 1987, 10, 342–346. [Google Scholar] [CrossRef]
  9. Weis, J.S.; Kim, K. Tributyltin is a teratogen in producing deformities in limbs of the fiddler crab,Uca pugilator. Arch. Environ. Contam. Toxicol. 1988, 17, 583–587. [Google Scholar] [CrossRef]
  10. Horiguchi, T.; Shiraishi, H.; Shimizu, M.; Yamazaki, S.; Morita, M. Imposex in Japanese gastropods (neogastropoda and mesogastropoda): Effects of tributyltin and triphenyltin from antifouling paints. Mar. Pollut. Bull. 1995, 31, 402–405. [Google Scholar] [CrossRef]
  11. Terlizzi, A.; Delos, A.L.; Garaventa, F.; Faimali, M.; Gerace, S. Limited effectiveness of marine protected areas: Imposex in Hexaplex trunculus (Gastropoda, Muricidae) populations from Italian marine reserves. Mar. Pollut. Bull. 2004, 48, 188–192. [Google Scholar] [CrossRef]
  12. Gibbs, P.E.; Bryan, G.W. Reproductive Failure in Populations of the Dog-Whelk, Nucella Lapillus, Caused by Imposex Induced by Tributyltin from Antifouling Paints. J. Mar. Biol. Assoc. UK 1986, 66, 767–777. [Google Scholar] [CrossRef]
  13. Gibbs, P.E.; Bryan, G.W. TBT-Induced Imposex in Neogastropod Snails: Masculinization to Mass Extinction. In Tributyltin: Case Study of an Environmental Contaminant; de Mora, S.J., Ed.; Cambridge University Press: Cambridge, UK, 1996; pp. 212–236. [Google Scholar]
  14. Horiguchi, T. Mechanism of Imposex Induced by Organotins in Gastropods. In Ecotoxicology of Antifouling Biocides; Arai, T., Harino, H., Ohji, M., Langston, W.J., Eds.; Springer: Tokyo, Japan, 2009; p. 111. [Google Scholar]
  15. Evans, S.M. TBT or not TBT?: That is the question. Biofouling 1999, 14, 117–129. [Google Scholar] [CrossRef]
  16. Konstantinou, I.K.; Albanis, T.A. Worldwide occurrence and effects of antifouling paint booster biocides in the aquatic environment: A review. Environ. Int. 2004, 30, 235–248. [Google Scholar] [CrossRef]
  17. Thomas, K.V.; Brooks, S. The Environmental Fate and Effects of Antifouling Paint Biocides. Biofouling 2010, 26, 73–88. [Google Scholar] [CrossRef]
  18. Kitano, Y.; Ito, T.; Suzuki, T.; Nogata, Y.; Shinshima, K.; Yoshimura, E.; Chiba, K.; Tada, M.; Sakaguchi, I. Synthesis and Antifouling Activity of 3-Isocyanotheonellin and Its Analogues. J. Chem. Soc. Perkin Trans. 2002, 1, 2251–2255. [Google Scholar] [CrossRef]
  19. Nogata, Y.; Kitano, Y.; Yoshimura, E.; Shinshima, K.; Sakaguchi, I. Antifouling Activity of Simple Synthetic Isocyanides Against Larvae of the Barnacle Balanus amphitrite. Biofouling 2004, 20, 87–91. [Google Scholar] [CrossRef]
  20. Kitano, Y.; Akima, C.; Yoshimura, E.; Nogata, Y. Anti-barnacle activity of novel simple alkyl isocyanides derived from citronellol. Biofouling 2011, 27, 201–205. [Google Scholar] [CrossRef]
  21. Kitano, Y.; Chiba, K.; Tada, M. Highly Efficient Conversion of Alcohols to Isocyanides. Synthesis 2001, 437–443. [Google Scholar] [CrossRef]
  22. Mihara, K.; Okada, I.; Chiba, K.; Kitano, Y. Facile Synthesis of N-Substituted Amides from Alkenes and Amides by a Brønsted Acid Mediated Electrophilic Addition Reaction. Synthesis 2014, 46, 1455–1462. [Google Scholar]
  23. Fukuda, T.; Wagatsuma, H.; Kominami, Y.; Nogata, Y.; Yoshimura, E.; Chiba, K.; Kitano, Y. Anti-barnacle Activity of Isocyanides Derived from Amino Acids. Chem. Biodivers. 2016, 13, 1502–1510. [Google Scholar] [CrossRef]
  24. Inoue, Y.; Takashima, S.; Nogata, Y.; Yoshimura, E.; Chiba, K.; Kitano, Y. Isocyanides Derived from α,α-Disubstituted Amino Acids: Synthesis and Antifouling Activity Assessment. Chem. Biodivers. 2018, 15, e1700571. [Google Scholar] [CrossRef]
  25. Takamura, H.; Ohashi, T.; Kikuchi, T.; Endo, N.; Fukuda, Y.; Kadota, I. Late-stage divergent synthesis and antifouling activity of geraniol–butenolide hybrid molecules. Org. Biomol. Chem. 2017, 15, 5549–5555. [Google Scholar] [CrossRef] [Green Version]
  26. Takamura, H.; Kikuchi, T.; Endo, N.; Fukuda, Y.; Kadota, I. Total Synthesis of Sarcophytonolide H and Isosarcophytonolide D: Structural Revision of Isosarcophytonolide D and Structure−Antifouling Activity Relationship of Sarcophytonolide H. Org. Lett. 2016, 18, 2110–2113. [Google Scholar] [CrossRef]
  27. Sjögren, M.; Johnson, A.-L.; Hedner, E.; Dahlström, M.; Göransson, U.; Shirani, H.; Bergman, J.; Jonsson, P.R.; Bohlin, L. Antifouling Activity of Synthesized Peptide Analogs of the Sponge Metabolite Barettin. Peptides 2006, 27, 2058–2064. [Google Scholar] [CrossRef]
  28. Qian, P.-Y.; Chen, L.; Xu, Y. Mini-review: Molecular Mechanisms of Antifouling Compounds. Biofouling 2013, 29, 381–400. [Google Scholar] [CrossRef]
  29. Liao, S.; Xu, Y.; Tang, Y.; Wang, J.; Zhou, X.; Xu, L.; Liu, Y. Design, Synthesis and Biological Evaluation of Soluble 2,5-Diketopiperazines Derivatives as Potential Antifouling Agents. RSC Adv. 2015, 5, 51020–51026. [Google Scholar] [CrossRef]
  30. Fusetani, N. Antifouling marine natural products. Nat. Prod. Rep. 2011, 28, 400–410. [Google Scholar] [CrossRef]
  31. Nishikawa, K.; Nakahara, H.; Shirokura, Y.; Nogata, Y.; Yoshimura, E.; Umezawa, T.; Okino, T.; Matsuda, F. Total Synthesis of 10-Isocyano-4-cadinene and Determination of Its Absolute Configuration. Org. Lett. 2010, 12, 904–907. [Google Scholar] [CrossRef]
  32. Nishikawa, K.; Nakahara, H.; Shirokura, Y.; Nogata, Y.; Yoshimura, E.; Umezawa, T.; Okino, T.; Matsuda, F. Total Synthesis of 10-Isocyano-4-cadinene and Its Stereoisomers and Evaluation of Antifouling Actitities. J. Org. Chem. 2011, 76, 6558–6573. [Google Scholar] [CrossRef]
  33. Nishikawa, K.; Umezawa, T.; Garson, M.J.; Matsuda, F. Confirmation of the Configurations of 10-Isothiocyano-4-cadinene through Synthesis. J. Nat. Prod. 2012, 75, 2232–2235. [Google Scholar] [CrossRef]
  34. Umezawa, T.; Oguri, Y.; Matsuura, H.; Yamazaki, S.; Suzuki, M.; Yoshimura, E.; Furuta, T.; Nogata, Y.; Serisawa, Y.; Matsuyama-Serisawa, K.; et al. Omaezallene from Red Alga Laurencia sp.: Structure Elucidation, Total Synthesis and Antifouling Activity. Angew. Chem. Int. Ed. 2014, 53, 3909–3912. [Google Scholar] [CrossRef]
  35. Umezawa, T.; Prakoso, N.I.; Kannaka, M.; Nogata, Y.; Yoshimura, E.; Okino, T.; Matsuda, F. Synthesis and Structure-Activity Relationship of Omaezallene Derivatives. Chem. Biodivers. 2019, 16, e1800451. [Google Scholar] [CrossRef]
  36. Umezawa, T.; Mizutani, N.; Matsuo, K.; Tokunaga, Y.; Matsuda, F.; Nehira, T. Assignment of Absolute Configuration of Bromoallenes by Vacuum-Ultraviolet Circular Dichroism (VUVCD). Molecules 2021, 26, 1296. [Google Scholar] [CrossRef]
  37. Umezawa, T.; Sato, A.; Ameda, Y.; Casalme, L.O.; Matsuda, F. Synthetic Study on Dolastatin 16: Concise and Scalable Synthesis of Two Unusual Amino Acid Units. Tetrahedron Lett. 2015, 56, 168–171. [Google Scholar] [CrossRef]
  38. Casalme, L.O.; Yamauchi, A.; Sato, A.; Petitbois, J.G.; Nogata, Y.; Yoshimura, E.; Okino, T.; Umezawa, T.; Matsuda, F. Total Synthesis and Biological Activity of Dolastatin 16. Org. Biomol. Chem. 2017, 15, 1140–1150. [Google Scholar] [CrossRef]
  39. Reddy, B.V.S.; Reddy, L.R.; Corey, E.J. Novel Acetoxylation and C−C Coupling Reactions at Unactivated Positions in α-Amino Acid Derivatives. Org. Lett. 2006, 8, 3391–3394. [Google Scholar] [CrossRef]
  40. Zhu, C.; Shen, X.; Nelson, S.G. Cinchona Alkaloid-Lewis Acid Catalyst Systems for Enantioselective Ketene−Aldehyde Cycloadditions. J. Am. Chem. Soc. 2004, 126, 5352–5353. [Google Scholar] [CrossRef]
  41. Shiina, I.; Kubota, M.; Ibuka, R. A Novel and Efficient Macrolactonization of ω-Hydroxycarboxylic Acids Using 2-Methyl-6-nitrobenzoic Anhydride (MNBA). Tetrahedron Lett. 2002, 43, 7535–7539. [Google Scholar] [CrossRef]
  42. Shiina, I.; Kubota, M.; Oshiumi, H.; Hashizume, M. An Effective Use of Benzoic Anhydride and Its Derivatives for the Synthesis of Carboxylic Esters and Lactones:  A Powerful and Convenient Mixed Anhydride Method Promoted by Basic Catalysts. J. Org. Chem. 2004, 69, 1822–1830. [Google Scholar] [CrossRef]
  43. Shiina, I.; Fukui, H.; Sasaki, A. Synthesis of Lactones Using Substituted Benzoic Anhydride as a Coupling Reagent. Nat. Protoc. 2007, 2, 2312–2317. [Google Scholar] [CrossRef]
  44. Narasaka, K.; Maruyama, K.; Mukaiyama, T. A Useful Method for the Synthesis of Macrocyclic Lactone. Chem. Lett. 1978, 7, 885–888. [Google Scholar] [CrossRef]
  45. Aurelio, L.; Brownlee, R.T.C.; Hughes, A.B. Solution-Phase Peptide Synthesis; Synthesis of ‘North-Western’ and ‘South-Eastern’ Fragments of the Antifungal Cyclodepsipeptide Petriellin A. Aust. J. Chem. 2008, 61, 615–629. [Google Scholar] [CrossRef]
Figure 1. Unusual amino acids in dolastatin 16 and previous total synthesis.
Figure 1. Unusual amino acids in dolastatin 16 and previous total synthesis.
Marinedrugs 20 00124 g001
Scheme 1. Syntheses of dolaphenvaline derivatives.
Scheme 1. Syntheses of dolaphenvaline derivatives.
Marinedrugs 20 00124 sch001
Scheme 2. Synthesis of dolamethylleuine derivatives.
Scheme 2. Synthesis of dolamethylleuine derivatives.
Marinedrugs 20 00124 sch002
Scheme 3. Synthesis of southern fragments. EDCI, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; DMAP, 4-dimethylaminopyridine; DMTMM, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate.
Scheme 3. Synthesis of southern fragments. EDCI, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; DMAP, 4-dimethylaminopyridine; DMTMM, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate.
Marinedrugs 20 00124 sch003
Scheme 4. Synthesis of dolastatin 16 derivative. DMTMM, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate; CMPI, 2-chloro-1-methylpyridimium iodide.
Scheme 4. Synthesis of dolastatin 16 derivative. DMTMM, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate; CMPI, 2-chloro-1-methylpyridimium iodide.
Marinedrugs 20 00124 sch004
Scheme 5. Synthesis of northern fragments. EDCI, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; DMAP, 4-dimethylaminopyridine; PyBrop: bromotripyrrolidinophosphonium hexafluorophosphate.
Scheme 5. Synthesis of northern fragments. EDCI, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; DMAP, 4-dimethylaminopyridine; PyBrop: bromotripyrrolidinophosphonium hexafluorophosphate.
Marinedrugs 20 00124 sch005
Figure 2. Compounds for evaluation of antifouling activity.
Figure 2. Compounds for evaluation of antifouling activity.
Marinedrugs 20 00124 g002
Table 1. Antifouling activities of synthetic samples against cypris larvae of A. amphitrite.
Table 1. Antifouling activities of synthetic samples against cypris larvae of A. amphitrite.
CompoundEC50 (μg/mL) 1EC50 (μM)LC50 (μg/mL) 2
1 3<0.03<0.03>10
2 3>10>17.0>10
3 31.171.92>10
241.741.86>10
Boc-30.791.30>10
210.600.96>10
224.626.47>10
250.901.32>10
293.276.52>10
CuSO4 30.100.63>10
1 EC50 (50% effective concentration), 2 LC50 (50% leathal concentration),3 according to [38].
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Casalme, L.O.; Katayama, K.; Hayakawa, Y.; Nakamura, K.; Yamauchi, A.; Nogata, Y.; Yoshimura, E.; Matsuda, F.; Umezawa, T. Effective Synthesis and Antifouling Activity of Dolastatin 16 Derivatives. Mar. Drugs 2022, 20, 124. https://doi.org/10.3390/md20020124

AMA Style

Casalme LO, Katayama K, Hayakawa Y, Nakamura K, Yamauchi A, Nogata Y, Yoshimura E, Matsuda F, Umezawa T. Effective Synthesis and Antifouling Activity of Dolastatin 16 Derivatives. Marine Drugs. 2022; 20(2):124. https://doi.org/10.3390/md20020124

Chicago/Turabian Style

Casalme, Loida O., Keisuke Katayama, Yoshiki Hayakawa, Kensuke Nakamura, Arisa Yamauchi, Yasuyuki Nogata, Erina Yoshimura, Fuyuhiko Matsuda, and Taiki Umezawa. 2022. "Effective Synthesis and Antifouling Activity of Dolastatin 16 Derivatives" Marine Drugs 20, no. 2: 124. https://doi.org/10.3390/md20020124

APA Style

Casalme, L. O., Katayama, K., Hayakawa, Y., Nakamura, K., Yamauchi, A., Nogata, Y., Yoshimura, E., Matsuda, F., & Umezawa, T. (2022). Effective Synthesis and Antifouling Activity of Dolastatin 16 Derivatives. Marine Drugs, 20(2), 124. https://doi.org/10.3390/md20020124

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop